Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06458595
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-13
First Post:
2024-06-09
Brief Title:
Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration nAMD
Sponsor:
Chengdu Origen Biotechnology Co Ltd
Organization:
Chengdu Kanghong Pharmaceutical Group Co Ltd
Study Overview
Official Title:
A Phase III Study to Evaluate the Tolerability Safety and Efficacy of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration nAMD
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
KH658 is a adeno-associated virus AAV vector-based gene therapy for suprachoroidal space injection The long-term stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain vision
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None